SOURCE: Pipex Pharmaceuticals, Inc.

March 30, 2007 08:00 ET

Pipex Pharmaceuticals to Host Webcast to Discuss Fourth Quarter and Year End 2006 Results

Webcast/Conference Call This Monday, April 2, at 8:30 a.m. EDT

ANN ARBOR, MI -- (MARKET WIRE) -- March 30, 2007 -- Pipex Pharmaceuticals, Inc. (OTCBB: PPXP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced that it will hold a conference call on Monday, April 2, 2007 at 8:30 a.m. EDT to discuss its fourth quarter and year end 2006 financial results. Steve H. Kanzer, Chairman and Chief Executive Officer of Pipex, will host the call. Pipex will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the webcast/conference call, please call toll free: 800-418-6860 (US); international dial-in: 973-935-8756. A visual presentation will be available at: http://www.visualwebcaster.com/event.asp?id=38758. The audio recording and visual presentation will be available for replay at http://www.pipexpharma.com for a period of at least15 days after the call.

About Pipex Pharmaceuticals, Inc.

Pipex Pharmaceuticals, Inc. ("Pipex") is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases Pipex's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). For further information, please visit, www.pipexpharma.com.

Contact Information

  • For Further Information Contact:

    Steve H. Kanzer, CPA, Esq.
    Chairman and Chief Executive Officer
    (734) 332-7800

    Charles Bisgaier, Ph.D.
    President
    (734) 332-7800